PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting

Heart

Volumn 92, Issue 3, 2006, Pages 377-381

  Marcucci, R ^a   Brogi, D ^b   Sofi, F ^b   Giglioli, C ^b   Valente, S ^b   Liotta, A Alessandrello ^b   Lenti, M ^b   Gori, A M ^b   Prisco, D ^b   Abbate, R ^b   Gensini, G F ^b  

^a Centro Trombosi   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; EVALUATION; FEMALE; GENETIC POLYMORPHISM; HEART LEFT VENTRICLE FUNCTION; HETEROZYGOSITY; HUMAN; KAPLAN MEIER METHOD; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; RISK FACTOR; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; FACTOR V; FEMALE; HOMOCYSTEINE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROTHROMBIN; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; STENTS; SYNDROME; THROMBOPHILIA;

EID: 33644525975     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.061895     Document Type: Article

References (37)

1. Keeley EC, Grines CL. Primary percutaneous coronary intervention for every patient with ST-segment elevation myocardial infarction: what stands in the way? Ann Intern Med 2004;141:298-304.
2. Radke PW, Kaiser A, Frost C, et al. Outcome after treatment of coronary in-stent restenosis; results from a systematic review using meta-analysis techniques. Eur Heart J 2003;24:266-73.
3. Margaglione M, Brancaccio V, De Lucia D, et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest 2000;118:1405-11.
4. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003;146:948-57.
5. Soeki T, Tamura Y, Shinohara H, et al. Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death. Int J Cardiol 2002;85:277-83.
6. Anvari A, Schuster E, Gottsauner-Wolf M, et al. PAI-1 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thromb Res 2001;103:103-7.
7. Strauss BH, Lau HK, Bowman KA, et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999;100:1616-22.
8. Prisco D, Fedi S, Antonucci E, et al. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 2001;104:181-6.
9. Genser D, Prachar H, Hauer R, et al. Relation of homocysteine, vitamin B12 and folate to coronary in-stent restenosis. Am J Cardiol 2002;89:495-9.
10. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350:2673-81.
11. Marcucci R, Prisco D, Brunelli T, et al. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiographically documented clinical recurrences after coronary angioplasty. Thromb Haemost 2000;83:826-32.
12. Schnyder G, Roffi M, Flammer Y, et al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 2002;23:726-33.
13. Koch W, Ndrepepa G, Mehilli J, et al. Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries. Arterioscler Thromb Vasc Biol 2003;23:2229-34.
14. Kojoglanian SA, Jorgensen MB, Wolde-Tsadik G, et al. Restenosis in intervened coronaries with hyperhomocysteinemia. Am Heart J 2003;146:1077-81.
15. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
16. Zairis MN, Ambrose JA, Manousakis SJ, et al. The impact of plasma levels of C-reactive protein, lipoprotein(a) and homocysteine on the long-term prognosis after successful coronary stenting. J Am Coll Cardiol 2002;40:1375-82.
17. Gazzaruso C, Garzaniti A, Falcone C, et al. Lipoprotein (a), apolipoprotein (a) polymorphism and restenosis after intracoronary stent placement in type 2 diabetic patients. J Diabetes Complications 2003;17:135-40.
18. Chobanian AV, Bakris GL, Black HR, and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, et al. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.
19. NCEP. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421.
20. Anon. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(suppl 1):S5-20.
21. Scanu AM. Atherothrombogenicity of lipoprotein(a): the debate. Am J Cardiol 1998;82:26Q-33Q.
22. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
23. Huber K. Plasminogen activator inhibitor type-1: basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 2001;11:183-93.
24. Hoekstra T, Geleijnse JM, Schouten EG, et al. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004;91:861-72.
25. Dudman NP. An alternative view of homocysteine. Lancet 1999;354:2072-4.
26. Korte W, Greiner J, Feldges A, et al. Increased Lp(a) levels are not a steady prothrombotic defect [letter]. Blood 2001;98:1993-4.
27. Lee YH, Choi SJ, Ji JD, et al. Lp(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000;19:324-5.
28. Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL6 induced Lp(a) and apoLp(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol 1998;18:984-90.
29. Tsikouris JP, Suarez JA, Meyerrose GE. Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 2002;42:1187-99.
30. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003;63:1821-54.
31. Zirlik A, Leugers A, Lohrmann J, et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 2004;91:674-82.
32. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19:217-46.
33. Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss heart study: a randomized controlled trial. JAMA 2002;288:973-9.
34. Marcucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 2003;75:1551-5.
35. Vermeulen EGJ, Stehouwer CDA, Twisk JWR, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trials. Lancet 2000;355:517-22.
36. Troen AM, Lutgens E, Smith DE, et al. The atherogenic effect of excess methionine intake. Proc Natl Acad Sci USA 2003;100:15089-94.
37. Reiner AP, Rosendaal FR, Reitsma PH, et al. factor V Leiden, prothrombin G20210A, and risk of sudden coronary death in apparently healthy persons. Am J Cardiol 2002;90:66-8.